See more : SHENZHEN BOSHIJIE (301608.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Todos Medical Ltd. (TOMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Todos Medical Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Alm. Brand A/S (ALMB.CO) Income Statement Analysis – Financial Results
- GC China Turbine Corp. (GCHT) Income Statement Analysis – Financial Results
- PT Perusahaan Gas Negara Tbk (PPAAF) Income Statement Analysis – Financial Results
- Odfjell Drilling Ltd. (ODL.OL) Income Statement Analysis – Financial Results
- Bunker Hill Mining Corp. (BNKR.CN) Income Statement Analysis – Financial Results
Todos Medical Ltd. (TOMDF)
About Todos Medical Ltd.
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.70M | 12.23M | 5.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.39M | 7.85M | 3.82M | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.31M | 4.38M | 1.39M | -29.64K | -25.65K | -24.08K | -20.70K | -11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 56.01% | 35.84% | 26.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 620.00K | 824.00K | 9.86M | 755.70K | 459.18K | 720.53K | 317.91K | 374.02K | 336.47K | 377.31K | 312.17 |
| General & Administrative | 0.00 | 9.36M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Selling & Marketing | 0.00 | 3.48M | -3.06M | -667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.85M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Other Expenses | 0.00 | 0.00 | -53.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.06M | 13.67M | 15.65M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Cost & Expenses | 17.44M | 21.52M | 19.47M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Interest Income | 0.00 | 28.61K | 13.37K | 959.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Interest Expense | 14.85M | 28.61M | 3.83M | 958.74K | 75.43K | 12.44K | 78.78K | 0.00 | 0.00 | ||
| Depreciation & Amortization | 750.00K | 763.00K | 96.00K | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 434.00 | 275.00 | 0.28 |
| EBITDA | -9.39M | -9.72M | -14.17M | -7.78M | -1.35M | -1.31M | -708.19K | -819.08K | -400.41K | -339.26K | -244.22 |
| EBITDA Ratio | -122.08% | -59.33% | -465.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.75M | -9.29M | -14.26M | -3.52M | -1.38M | -1.34M | -728.89K | -830.98K | -400.85K | -339.53K | -244.49 |
| Operating Income Ratio | -126.68% | -75.93% | -273.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.23M | -34.03M | -15.51M | -8.30M | 921.34K | -1.34M | 75.43K | 12.44K | 78.78K | -42.29K | -11.63 |
| Income Before Tax | -24.98M | -43.31M | -29.77M | -11.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -381.82K | -256.12 |
| Income Before Tax Ratio | -324.64% | -354.16% | -571.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | 31.61M | 2.63M | -2.01M | 871.34K | -2.68M | 0.00 | 0.00 | 0.00 | -38.18K | -25.37 |
| Net Income | -24.99M | -74.92M | -32.40M | -9.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -343.64K | -230.75 |
| Net Income Ratio | -324.81% | -612.60% | -622.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
| Weighted Avg Shares Out (Dil) | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
Todos Medical says Provista Diagnostics to provide PCR-based monkeypox testing for clients in New Jersey
Todos Medical wins first lab services contract for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Todos Medical poised to branch into MonkeyPox testing as Provista Diagnostics begins validation plan
Todos Medical says new study highlights case for use of dietary supplement product Tollovid
Todos Medical partners with Amerimmune Diagnostics on long-COVID biomarker panel
Todos Medical and 3CL Pharma hail return to better health in long COVID case through use of Tollovid
Todos Medical plans open label extension of Phase 2 trial of Tollovir in hospitalized Covid patients after encouraging biomarker data
Todos Medical reveals promising data from sponsored study of dietary supplement Tollovid in respondents with COVID-19
Todos Medical says lab Provista to launch UTI pathogen PCR assay commercially
Todos Medical reports that long COVID patient felt "90 to 95% better" within five days of taking 3CL protease inhibitor dietary supplement Tollovid
Source: https://incomestatements.info
Category: Stock Reports